Core Laboratories (NYSE: CLB) CEO purchases 5,000 shares in open-market trade
Rhea-AI Filing Summary
Core Laboratories Inc. reported that Chairman and CEO Bruno Lawrence purchased 5,000 shares of common stock on July 31, 2026 at $10.78 per share, described as a purchase in open market or private transaction. After this trade, his directly held stake totaled 262,438 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 5,000 shares
Net Buy
1 txn
Insider
Bruno Lawrence
Role
Chairman and CEO
Bought
5,000 shs ($54K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 5,000 | $10.78 | $54K |
Holdings After Transaction:
Common Stock — 262,438 shares (Direct)
Key Figures
Shares purchased: 5,000 shares
Purchase price: $10.78 per share
Holdings after transaction: 262,438 shares
+1 more
4 metrics
Shares purchased
5,000 shares
Common stock bought on July 31, 2026
Purchase price
$10.78 per share
Price for Core Laboratories common stock transaction
Holdings after transaction
262,438 shares
Direct common stock ownership by Bruno Lawrence after purchase
Net buy shares
5,000 shares
Net change from reported insider transactions
Key Terms
Purchase in open market or private transaction, Rule 10b5-1 trading plans, beneficial ownership
3 terms
Purchase in open market or private transaction financial
"transaction_code_description: "Purchase in open market or private transaction""
Rule 10b5-1 trading plans regulatory
"Footnotes may reference <b>Rule 10b5-1 trading plans</b> or pre-arranged trading arrangements"
Rule 10b5-1 trading plans are written, pre-arranged instructions that allow company insiders (such as executives or directors) to automatically buy or sell their company's stock at specified times or under set conditions, like a standing instruction or automated thermostat for trades. They matter to investors because these plans provide a legal defense against insider‑trading accusations and create predictable insider trading patterns that can help signal whether sales are routine portfolio management or potentially meaningful to the company’s outlook.
beneficial ownership financial
"Any disclaimers of <b>beneficial ownership</b>"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider stock transaction did CLB report for its CEO?
Core Laboratories reported that Chairman and CEO Bruno Lawrence purchased 5,000 shares of its common stock on July 31, 2026. The shares were bought at $10.78 per share, classified as a purchase in open market or private transaction for his direct account.
What type of transaction was reported in the CLB Form 4?
The Form 4 for Core Laboratories lists a purchase of common stock by CEO Bruno Lawrence. It is coded as a non‑derivative transaction, described specifically as a “Purchase in open market or private transaction” involving 5,000 shares at $10.78 per share.
Does the CLB CEO’s Form 4 indicate use of a Rule 10b5-1 trading plan?
The data for this Form 4 shows the Rule 10b5-1 checkbox is not marked as affirming a trading plan. There is no accompanying footnote describing any Rule 10b5-1 trading arrangement for Bruno Lawrence’s 5,000‑share Core Laboratories purchase.